Recently ICU Medical Inc. (ICUI) planned a full market release of its new MicroCLAVE Clear Neutral Displacement Needlefree Connector in the Annual Scientific Meeting of the Society for Healthcare Epidemiology of America (SHEA), which is being held in Dallas from 1st to 4th April.
Providing a proper picture of the fluid path, MicroCLAVE Clear enables physicians to ensure effective clearing of the blood and blood residual from patient catheter with a very low flush volume. Additionally, it works as an effective microbial barrier against bacteria transfer and contamination. The full set of MicroCLAVE connectors also includes the original MicroCLAVE and the antimicrobial MicroCLAVE.
ICU Medical, based on its recent studies, expects this new generation MicroCLAVE Clear to be more efficient than the market competing products like the positive displacement MaxPlus of CareFusion (CFN) or the negative displacement ClearLink by Baxter (BAX). The company with this launch thus expects solid growth and an increase in its market share in the competitive medical technology industry.
The segments of ICU Medical include custom I.V. systems, closed delivery systems for hazardous drugs, needleless I.V. connectors, catheters and cardiac monitoring systems. In the past few years, the company is showing consistent year-over-year growth.
During the fourth quarter of fiscal 2010, revenue was up 8.3% year over year, aided by a better product mix in favor of higher value-added products. Also the company has started the product shipments from its newly established Slovakian plant.
Additionally, the company is focusing on improved manufacturing facilities, quality controls, and research and development. It is also adopting several cost containment efforts like reduction in labor costs and investment in inventory.
BAXTER INTL (BAX): Free Stock Analysis Report
CAREFUSION CORP (CFN): Free Stock Analysis Report
ICU MEDICAL INC (ICUI): Free Stock Analysis Report
Zacks Investment Research
